OBJECTIVES: To evaluate critically the evidence linking psychotropic drugs
with falls in older people.
DESIGN: Fixed-effects meta-analysis.
DATA SOURCES: English-language articles in MEDLINE (1966 - March 1996) inde
xed under accidents or accidental falls and aged or age factors; bibliograp
hies of retrieved papers.
STUDY SELECTION: Systematic evaluation of sedative/hypnotic, antidepressant
, or neuroleptic use with falling in people aged 60 and older.
DATA EXTRACTION: Study design, inclusion and exclusion criteria, setting, s
ample size, response rate, mean age, method of medication verification and
fall assessment, fall definition, and the number of fallers and non-fallers
taking specific classes of psychotropic drugs.
RESULTS: Forty studies, none randomized controlled trials, met eligibility
criteria. For one or more falls, the pooled odds ratio (95% confidence inte
rval) was 1.73 (95% CI, 1.52-1.97) for any psychotropic use; 1.50 (95% CI,
1.25-1.79) for neuroleptic use; 1.54 (95% CI, 1.40-1.70) for sedative/hypno
tic use; 1.66 (95% CI, 1.4-1.95) for any antidepressant use (mainly TCAs);
1.51 (95% CI, 1.14-2.00) for only TCA use; and 1.48 (95% CI, 1.23-1.77) for
benzodiazepine use, with no difference between short and long acting benzo
diazepines. For neuroleptics in psychiatric inpatients, the pooled OR was 0
.41 (95% CI, 0.21-.82); for all other patients, the pooled OR was 1.66 (95%
CI, 1.38-2.00). Comparing greater than or equal to 1 with greater than or
equal to 2 falls, mean subject age <75 versus greater than or equal to 75 y
ears old, communities with <35% versus greater than or equal to 35% fallers
, or subject place of residence did not affect the pooled OR. Increased fal
ls occurred in patients taking more than one psychotropic drug.
CONCLUSION: There is a small, but consistent, association between the use o
f most classes of psychotropic drugs and falls. The evidence to date, howev
er, is based solely on observational data, with minimal adjustment for conf
ounders, dosage, or duration of therapy. The incidence of falls and their c
onsequences in this population necessitate that future large randomized con
trolled trials of any medication in older persons should measure falls pros
pectively as an adverse outcome event.